ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43.
Eveline S Arnold, Shuo-Chien Ling, Stephanie C Huelga, Clotilde Lagier-Tourenne, Magdalini Polymenidou, Dara Ditsworth, Holly B Kordasiewicz, Melissa McAlonis-Downes, Oleksandr Platoshyn, Philippe A Parone, Sandrine Da Cruz, Kevin M Clutario, Debbie Swing, Lino Tessarollo, Martin Marsala, Christopher E Shaw, Gene W Yeo, Don W Cleveland
Proceedings of the National Academy of Sciences of the United States of America · 2013 · Vol. 110 (8) · pp. E736-45
Abstract
Transactivating response region DNA binding protein (TDP-43) is the major protein component of ubiquitinated inclusions found in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) with ubiquitinated inclusions. Two ALS-causing mutants (TDP-43(Q331K) and TDP-43(M337V)), but not wild-type human TDP-43, are shown here to provoke age-dependent, mutant-dependent, progressive motor axon degeneration and motor neuron death when expressed in mice at levels and in a cell type-selective pattern similar to endogenous TDP-43. Mutant TDP-43-dependent degeneration of lower motor neurons occurs without: (i) loss of TDP-43 from the corresponding nuclei, (ii) accumulation of TDP-43 aggregates, and (iii) accumulation of insoluble TDP-43. Computational analysis using splicing-sensitive microarrays demonstrates alterations of endogenous TDP-43-dependent alternative splicing events conferred by both human wild-type and mutant TDP-43(Q331K), but with high levels of mutant TDP-43 preferentially enhancing exon exclusion of some target pre-mRNAs affecting genes involved in neurological transmission and function. Comparison with splicing alterations following TDP-43 depletion demonstrates that TDP-43(Q331K) enhances normal TDP-43 splicing function for some RNA targets but loss-of-function for others. Thus, adult-onset motor neuron disease does not require aggregation or loss of nuclear TDP-43, with ALS-linked mutants producing loss and gain of splicing function of selected RNA targets at an early disease stage.
Funding 15 grants
| Grant | Funder |
|---|---|
| R01 HG004659 | NHGRI NIH HHS (United States) |
| T32 GM008666 | NIGMS NIH HHS (United States) |
| R01 NS075449 | NINDS NIH HHS (United States) |
| MC_G1000733 | Medical Research Council (United Kingdom) |
| HG004659 | NHGRI NIH HHS (United States) |
| NS075449 | NINDS NIH HHS (United States) |
| T32 AG 000216 | NIA NIH HHS (United States) |
| 089701 | Wellcome Trust (United Kingdom) |
| T32 AG000216 | NIA NIH HHS (United States) |
| K99 NS075216 | NINDS NIH HHS (United States) |
| G0300329 | Medical Research Council (United Kingdom) |
| NS075216 | NINDS NIH HHS (United States) |
| G0900688 | Medical Research Council (United Kingdom) |
| RC1 NS069144 | NINDS NIH HHS (United States) |
| NS069144 | NINDS NIH HHS (United States) |